News for 'Serum Institute of India CEO Adar Poonawalla'

Serum CEO Adar Poonawalla to get 'Y' category security

Serum CEO Adar Poonawalla to get 'Y' category security

Rediff.com28 Apr 2021

Poonawalla has been getting threats from various groups regarding the COVID-19 vaccine supplies.

Adar Poonawalla Wants To Buy RCB

Adar Poonawalla Wants To Buy RCB

Rediff.com1 Oct 2025

It is not yet clear if Diageo Plc is looking to sell its complete stake in RCB.

What is Adar Poonawalla up to?

What is Adar Poonawalla up to?

Rediff.com4 May 2021

What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.

'Please be patient': Adar Poonawalla to nations waiting for Covishield

'Please be patient': Adar Poonawalla to nations waiting for Covishield

Rediff.com21 Feb 2021

Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.

Nod for Covid vaccine in next few days: Serum Institute's Poonawalla

Nod for Covid vaccine in next few days: Serum Institute's Poonawalla

Rediff.com29 Dec 2020

The Serum Institute of India has stockpiled 40 mn-50 mn doses and is adding more every week. Most of these will come to India.

Hopeful of launching Covovax by Oct: Adar Poonawalla

Hopeful of launching Covovax by Oct: Adar Poonawalla

Rediff.com6 Aug 2021

On production capacity of Covishield, the vaccine being manufactured and supplied by Serum in India under a licensing agreement with Oxford and AstraZeneca, he said the present capacity is 130 million doses per month and always try to increase it further.

As Covid cases rise, Serum Institute restarts manufacture of Covishield

As Covid cases rise, Serum Institute restarts manufacture of Covishield

Rediff.com12 Apr 2023

Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection.

5 dead in Serum Institute fire; Covishield facility unaffected

5 dead in Serum Institute fire; Covishield facility unaffected

Rediff.com21 Jan 2021

Covishield vaccine production won't be hit due to the fire, Serum Institute of India Chief Executive Officer Adar Poonawalla said. The Manjari facility is where the Covishield vaccine used in the nationwide inoculation drive against the pandemic is made.

Where You Can See This Rs 167.2 Crore Painting

Where You Can See This Rs 167.2 Crore Painting

Rediff.com10 Apr 2026

Raja Ravi Varma's painting Yashoda and Krishna was recently acquired by Cyrus Poonawalla and his son, the vaccine manufacturer's CEO Adar Poonawalla, for Rs 167.2 crore, setting a new benchmark for modern Indian art.

Serum Institute's race to produce COVID-19 vaccine

Serum Institute's race to produce COVID-19 vaccine

Rediff.com23 May 2020

'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'

Bharat Biotech, Serum Institute to jointly roll out vaccines

Bharat Biotech, Serum Institute to jointly roll out vaccines

Rediff.com5 Jan 2021

In a joint statement posted on their respective twitter accounts, the companies said Serum Institute Chief Executive Officer Adar Poonawalla and Bharat Biotech Chairman Krishna Ella communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines.

COVID-19 vaccine by Oct-Nov: Serum Institute CEO

COVID-19 vaccine by Oct-Nov: Serum Institute CEO

Rediff.com22 Jul 2020

Poonawalla, during an interaction with Odisha Chief Minister Naveen Patnaik through a video conference, expressed optimism that the COVID-19 vaccine could be ready by October-November this year and the next phase of the trial can start in mid-August in India. According to a press note released by the CMO, Poonawalla has informed that the Oxford University vaccine has shown promising results in the first phase trial.

WHO reminds Serum Institute of COVAX commitments

WHO reminds Serum Institute of COVAX commitments

Rediff.com18 May 2021

COVAX, 'the global COVID vaccine equity scheme', has so far delivered 65 million doses to 124 countries and economies but it is dependent on countries and manufacturers honouring their commitments.

Can't ramp up vaccine production overnight: SII's Adar Poonawalla

Can't ramp up vaccine production overnight: SII's Adar Poonawalla

Rediff.com3 May 2021

Poonawalla, who is in London, however, noted that the company is making every effort to enhance production of Covishield amid the second wave of COVID in the country.

'Vaccine shortage can't be blamed on Adar Poonawalla'

'Vaccine shortage can't be blamed on Adar Poonawalla'

Rediff.com16 Aug 2021

'It was unfair to expect him to continue to keep on supplying vaccines without being given a firm commitment or a financial grant of any sort.'

Serum Institute began its journey in a small lab in stud farm

Serum Institute began its journey in a small lab in stud farm

Rediff.com16 Jan 2021

The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.

Why Modi visited Serum's Covid vaccine unit

Why Modi visited Serum's Covid vaccine unit

Rediff.com10 Dec 2020

The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.

Tycoons At Radhika-Anant's Wedding

Tycoons At Radhika-Anant's Wedding

Rediff.com12 Jul 2024

Businessmen from all over the world attended Radhika Merchant and Anant Ambani's wedding at the Jio World Convention Centre, Bandra Kurla Complex, north west Mumbai, on Friday, July 12, 2024.

WHO clears Serum Institute's Covovax for emergency use

WHO clears Serum Institute's Covovax for emergency use

Rediff.com18 Dec 2021

'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.

Scamsters dupe SII of over Rs 1cr posing as Adar Poonawala

Scamsters dupe SII of over Rs 1cr posing as Adar Poonawala

Rediff.com11 Sep 2022

An FIR was launched against some unidentified persons for cheating the SII for more than Rs 1 crore, said the officials on Sunday.

Serum Institute seeks regular marketing approval for Covishield

Serum Institute seeks regular marketing approval for Covishield

Rediff.com25 Oct 2021

If the DCGI grants regular marketing authorisation, Covishied will be the second vaccine in the world to receive such approval.

Serum seeks indemnity from liability; says 'rules should be same for everyone'

Serum seeks indemnity from liability; says 'rules should be same for everyone'

Rediff.com3 Jun 2021

The development comes after requests for indemnity and exemption from bridging trials have been made by Pfizer and Moderna to the Indian government.

Serum Institute ready to roll out Covid vaccine

Serum Institute ready to roll out Covid vaccine

Rediff.com3 Jan 2021

The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.

Meet Adar Poonawala, India's COVID-19 vaccine man

Meet Adar Poonawala, India's COVID-19 vaccine man

Rediff.com6 Aug 2020

Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine. Sohini Das profiles its 39-year-old CEO.

Poonawalla confirms interest in acquiring RCB

Poonawalla confirms interest in acquiring RCB

Rediff.com22 Jan 2026

Pharma tycoon Adar Poonawalla has emerged as a potential suitor for the Indian Premier League franchise Royal Challengers Bengaluru, sparking fresh speculation around a possible change in ownership of one of the league's most high-profile teams.

Serum Institute set to sign deal with Centre for Covishield

Serum Institute set to sign deal with Centre for Covishield

Rediff.com9 Dec 2020

By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.

Serum Institute to provide Covid vaccine at Rs 250 a dose

Serum Institute to provide Covid vaccine at Rs 250 a dose

Rediff.com8 Aug 2020

Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.

Serum to launch Covid vaccine for children in 6 months: Poonawalla

Serum to launch Covid vaccine for children in 6 months: Poonawalla

Rediff.com14 Dec 2021

Currently, Covishield and other COVID vaccines are approved for people above the age of 18 years.

Novavax set for India launch with Serum Institute as partner

Novavax set for India launch with Serum Institute as partner

Rediff.com15 Jun 2021

The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das

Why Covishield Production Has Resumed

Why Covishield Production Has Resumed

Rediff.com20 Apr 2023

'I understand some people are comfortable getting a Covishield shot as their third dose.'

Need Rs 3,000 cr to ramp up vaccine production: SII CEO

Need Rs 3,000 cr to ramp up vaccine production: SII CEO

Rediff.com6 Apr 2021

Serum Institute along with other vaccine producers have agreed with the government to sacrifice profits. There is no vaccine industry on the planet that has agreed to provide vaccines at such a subsidised price, he added.

Serum Inst to resume Covid vaccine trials after DCGI nod

Serum Inst to resume Covid vaccine trials after DCGI nod

Rediff.com12 Sep 2020

'Once DCGI will give us the permission to restart the trials in India, we will resume the trials,' Serum Institute of India (SII) said in a statement.

Poonawala's Serum Inst to soon launch India's first cervical cancer vaccine

Poonawala's Serum Inst to soon launch India's first cervical cancer vaccine

Rediff.com1 Sep 2022

India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400, Serum Institute of India CEO Adar Poonawalla said on Thursday.

Reduce booster gap to 6 months: Serum Institute to govt

Reduce booster gap to 6 months: Serum Institute to govt

Rediff.com12 Apr 2022

Poonawalla noted that reducing the timeframe would give "real relief" to the people who want to travel abroad.

What's Zuckerberg Doing In India?

What's Zuckerberg Doing In India?

Rediff.com4 Mar 2024

Business tycoons at the Ambani's pre-wedding celebrations at Jamnagar, Gujarat.

'Hope you change your mind': Poonawalla to Djokovic

'Hope you change your mind': Poonawalla to Djokovic

Rediff.com18 Feb 2022

Serum CEO Adar Poonawalla posted a video of him playing tennis, with a message for the unvaccinated Novak Djokovic.

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

India's Cricket Boom Is Just Beginning

India's Cricket Boom Is Just Beginning

Rediff.com9 Oct 2025

'We have just scratched the surface because cricket has been around for the longest time.'

Serum distances from executive's criticism of govt

Serum distances from executive's criticism of govt

Rediff.com23 May 2021

SII executive director Suresh Jadhav on Friday alleged that the government began inoculating people from multiple age groups without taking into account the available stock of vaccines and the WHO guidelines.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'